Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Eastern European Results Roundup: Grindeks, Alkaloid, Olainfarm, Podravka, Sopharma

Several Eastern European generics companies achieved sales growth in 2018. Looking ahead, Grindeks plans to strengthen its presence in Russia and other CIS countries, Alkaloid is set to continue investing in production facilities and technologies, while Olainfarm looks to upgrade its product dossiers.

Europe Companies

Accord Agrees Leuprolide Deal as Part of Differentiation Strategy

Accord is furthering its push into added-value medicines by entering into a licensing agreement for Foresee’s injectable suspension leuprolide injectable.
Value-Added Medicines Deals

Zentiva Set To Acquire Romania's Solacium

Zentiva has signed its first acquisition after it was carved out from Sanofi last year to become an independent company, entering into a shared purchase agreement with Siyiara to acquire Romania-based food supplement and OTC medicines producer Solacium.

Romania M & A
See All

Deals Explore this Topic

Set Alert for Deals

Accord Agrees Leuprolide Deal as Part of Differentiation Strategy

Accord is furthering its push into added-value medicines by entering into a licensing agreement for Foresee’s injectable suspension leuprolide injectable.
Value-Added Medicines Deals

Aceto Strikes Deal To Offload Rising For Just US$15m

Aceto has struck a deal to sell its Rising Pharmaceuticals unit and related businesses to Shore Suven Pharma for US$15 million. The agreement comes shortly after Aceto agreed to divest its chemicals business assets for US$338 million after filing Chapter 11 bankruptcy petitions in the US.

Strategy Deals

Selexis And Turgut Expand Biosimilar Partnership With A Further Two Licensing Agreements

Selexis and Turgut have further expanded their biosimilar development partnership by signing commercial license agreements for two undisclosed biosimilar antibodies. Building on previous deals signed in July 2016 and December 2017, the companies are now working together to develop biosimilars to treat oncology and inflammatory diseases.

Biosimilars Deals
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

FDA Warns Teva's Actavis Over Quality Concerns

Quality issues and inconsistencies with laser-drilled tablet manufacturing processes at Teva’s Actavis have been flagged up by the FDA following an audit last July at the firm’s plant in Florida, US. The agency noted that similar cGMP observations were found during inspections in 2013, 2016 and 2017.

United States Manufacturing

Akorn Faces Hurdles In Returning To Path Of Profitable Growth

A new management team at Akorn is making progress on moving on from Fresenius Kabi’s ill-fated takeover bid; but putting manufacturing problems behind the US injectables and ophthalmics specialist is proving difficult.
Business Strategies Sales & Earnings

India’s Orchid Pharma Is Back On The Market

An acrimonious end to a takeover bid for bankrupt Indian player Orchid Pharma has reopened the pathway for previously interested parties to table fresh bids.
India Generic Drugs
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Eastern European Results Roundup: Grindeks, Alkaloid, Olainfarm, Podravka, Sopharma

Several Eastern European generics companies achieved sales growth in 2018. Looking ahead, Grindeks plans to strengthen its presence in Russia and other CIS countries, Alkaloid is set to continue investing in production facilities and technologies, while Olainfarm looks to upgrade its product dossiers.

Europe Companies

Akorn Faces Hurdles In Returning To Path Of Profitable Growth

A new management team at Akorn is making progress on moving on from Fresenius Kabi’s ill-fated takeover bid; but putting manufacturing problems behind the US injectables and ophthalmics specialist is proving difficult.
Business Strategies Sales & Earnings

Perrigo Persists On Pepcid As Prescription Profit Plummets

Perrigo has won a US appeals court ruling on its generic version of Pepcid Complete. However, the company’s Prescription generics business saw a 15% drop in sales and a 28% decline in operating profit as the firm reported its 2018 results, ahead of plans to separate the Prescription unit from the company as it transitions to become a ‘self-care’ company.

United States Generic Drugs
See All

People Explore this Topic

Set Alert for People

Sandoz Head Francis To Leave Amid Move Towards Autonomy

Sandoz’ drive to greater efficiency and stronger profit margins through a group-wide transformation process has prompted the division’s global head, Richard Francis, to step down.
Leadership Appointments

People Roundup – 7 March 2019

Biocon believes its new biologics chief in India will lead the firm to become a “major global player”, Glenmark names Riva to lead its recently spun-off innovation business, and Recipharm bolsters its management team by adding Chouhan to lead sales activity in North America.

Appointments Companies

Acino Adds Four To Senior Management Team

Acino has bolstered its senior management team with four appointments, as the Swiss firm aims to strengthen its position as a high-quality pharmaceutical company focusing on emerging markets.

Appointments Leadership
See All
UsernamePublicRestriction

Register